Illumina Inc (ILMN) shares reached a new 52-week high of $231.82. Over the past year, the stock has increased by 126.57%. The company is trading at a price-to-book ratio of 11.83, and the gross margin for the last twelve months (as of Q2 2026) was 67.94%. According to InvestingPro, the shares currently appear overvalued relative to their fair value.
Among other recent events: Illumina announced a bond issuance of $300 million to refinance existing debt. The funds are intended to be used for the repayment of bonds with a 4.650% coupon, maturing in 2026.
Analysts have adjusted their ratings. Freedom Broker downgraded its rating from 'buy' to 'hold', lowering the target price to $185. Canaccord revised its target to $205, noting that Q2 results exceeded expectations due to the placement of NovaSeq X systems and growth in clinical consumables sales. Stifel raised its target price to $225 while maintaining a 'buy' rating, emphasizing strong demand for sequencing systems. Guggenheim increased its target to $226, also maintaining 'buy', after earnings and revenue surpassed consensus forecasts.
Related articles
